Results 101 to 110 of about 333,660 (389)

Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis

Advanced Science, EarlyView.
Clathrin Light Chain B (CLTB) drives hepatocellular carcinoma progression through dual pathways: intracellularly, it activates the NF‐κB–PCLAF axis to enhance small extracellular vesicle (sEV) uptake and tumor proliferation; extracellularly, CLTB‐enriched sEVs bind SH3KBP1 to inhibit its degradation, inducing angiogenesis and vascular leakage ...
Xiaoke Sun, Junchen Guo, Ning Zhao, Guanghua Cui, Yun Bai, Meijuan Ding, Yi Xu, Yu Yang   +7 more
wiley   +1 more source

Assessment of the Prevalence of Markers of Monoinfection with Hepatitis C Virus and Coinfection with Hepatitis C and B Viruses among the Personnel of Medical Institutions of an Endemic Region

Эпидемиология и вакцинопрофилактика
Relevance. Parenteral viral hepatitis B (HBV) and C (HCV) affect not only millions of people, but also healthcare workers due to professional contacts, which lead to the progression of liver pathology and a reduction in medical activity. Numerous studies
M. P. Kostinov, N. A. Magomedova, I. A. Khrapunova, A. V. Linok, E. Yu. Malinnikova, G. I. Alatortseva, L. N. Pritvorova, L. N. Nesterenko, I. I. Amiantova, V. V. Dotsenko, V. Yu. Kabargina, V. B. Polishchuk, M. N. Loktionova, A. A. Besshaposhnikova   +13 more
doaj   +1 more source

Fine Mapping of the MHC Region Identifies Novel Variants Associated with HBV-Related Hepatocellular Carcinoma in Han Chinese

Journal of Hepatocellular Carcinoma, 2021
Haoming Mai,1,* Jiaxuan Chen,1,* Haitao Chen,1,2,* Zhiwei Liu,3,* Guanlin Huang,1 Jialin Wang,1 Qianyi Xiao,4 Weihua Ren,5 Bin Zhou,1 Jinlin Hou,1 Deke Jiang1 1State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of ...
Mai H, Chen J, Chen H, Liu Z, Huang G, Wang J, Xiao Q, Ren W, Zhou B, Hou J, Jiang D   +10 more
doaj  

SOX2 Represses Hepatitis B Virus Replication by Binding to the Viral EnhII/Cp and Inhibiting the Promoter Activation

Viruses, 2020
Hepatitis B virus (HBV) replication is controlled by four promoters (preS1, preS2, Cp, and Xp) and two enhancers (EnhI and EnhII). EnhII stimulates Cp activity to regulate the transcriptions of precore, core, polymerase, and pregenomic RNAs, and ...
Hua Yang, Jiayin Mo, Qi Xiang, Peiyi Zhao, Yunting Song, Ge Yang, Kailang Wu, Yingle Liu, Weiyong Liu, Jianguo Wu   +9 more
doaj   +1 more source

Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now [PDF]

, 2015
Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver
Cuestas, María Luján, Eguibar, Nair, Gonzalez, Rodrigo Horacio, Nusblat, Alejandro David, Perazzo, Priscila   +4 more
core   +1 more source

An HBV-encoded miRNA activates innate immunity to restrict HBV replication

Journal of Molecular Cell Biology, 2019
We previously identified that hepatitis B virus (HBV) encodes a microRNA (HBV-miR-3) that restrains HBV replication by targeting the HBV transcript. However, whether HBV-miR-3 affects host innate immunity to modulate HBV replication remains unclear. Here,
Xiaoqing Zhao, Lu Sun, Ting Mu, Jianying Yi, Chaoqun Ma, Hong Xie, Min Liu, Hua Tang   +7 more
semanticscholar   +1 more source

B‐EPIC: A Transformer‐Based Language Model for Decoding B Cell Immunodominance Patterns

Advanced Science, EarlyView.
B‐Epic: Achieving high‐accuracy B cell epitope prediction through Transformer architecture. Comprehensive validation demonstrates B‐Epic's robust performance across diverse datasets. B‐Epic facilitates vaccine development for H. pylori and EBV, addressing critical public health challenges.
Jun‐Ze Liang, Youtao Wang, Cong Sun, Tao Liu, Zengfeng Wu, Lipeng Chen, Lina Chen, Penglin Li, Zhengkang Li, Cangui Zhang, Bingyun Lu, Ye Chen, Bing Gu, Qian Zhong, Xin Wei Wang, Mu‐Sheng Zeng, Jinping Liu   +16 more
wiley   +1 more source

Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations [PDF]

, 1990
The morphologic evolution of hepatitis B virus (HBV) liver disease in 45 hepatic allograft recipients who were HBV surface-antigen positive (HBs-Ag+) at the time of liver replacement and who survived for more than 60 days was studied by routine ...
Demetris, AJ, Fung, JJ, Iwaki, Y, Ming, W, Starzl, TE, Sysyn, G, Todo, S, Trager, J, Van Thiel, DH   +8 more
core   +1 more source

Hepatitis B among Pacific Islanders in Southern California: how is health information associated with screening and vaccination? [PDF]

, 2010
We measured Hepatitis B virus (HBV) transmission knowledge and self-reported screening/testing behavior among Pacific Islanders (Guamanians/Chamorros, Samoans, and Tongans) in Southern California. We also examined access and trust by Pacific Islanders of
Anna J. Kim, B Custer, Jay Aromin, Jonathan Lepule, K-Q Hu, Lois M. Takahashi, Lola Sablan-Santos, Louise Young, Lourdes Flores Quitugua, Rose Perez, SP Grytdal, Steve Young, Tony Maguadog   +12 more
core   +3 more sources

HBV replication inhibitors

Antiviral Research, 2020
Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by nucleos(t)ide analogs (NAs) that profoundly but incompletely suppress DNA synthesis by the viral reverse transcriptase. Residual HBV replication during NA therapy contributes to maintenance of the critical
Claire Pierra Rouviere, Cyril B. Dousson, John E. Tavis   +2 more
openaire   +3 more sources